Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977611 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL3925606 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL30824585 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL3926825 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL28366949 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL2039471 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL31095337 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL28366948 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL3536308 | 0.95 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL3163175 | 0.95 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496084-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | claimed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | claimed |
| EP-4746964-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4683527-A1 | VAPORIZABLE ALKALOID COMPOSITIONS AND METHODS OF USE THEREOF | Ready Mix Naturals, LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12486276-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-119529236-A | Epoxy resin composition, epoxy resin composition containing reinforcing fibers, prepreg, thermoplastic resin, and fiber-reinforced plastic | 日铁化学材料株式会社 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025017078-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| US-20040089613-A1 | Removal of zinc salts from nonaqueous synthesis solutions comprising zinc alkoxides or zinc amides | CONSORTIUM FUR ELECKTROCHEMISCHE INDUSTRIE GMBH & CO. KG | 2004-05-13 | — | — | US | disclosed |
| EP-1405839-A1 | Process for separating zinc salts from zinc alcoholates or zinc amides containing non-aqueous synthesis solvents | Consortium für elektrochemische Industrie GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002098853-A2 | INHIBITORS OF CELL PROLIFERATION, ANGIOGENESIS, FERTILITY, AND MUSCLE CONTRACTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6184229-B1 | 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy | SANOFI-SYNTHELABO (FR) | 2001-02-06 | — | — | US | disclosed |
| CN-1262680-A | 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy | SANOFI SYNTHELABO (FR) | 2000-08-09 | — | — | CN | disclosed |
| EP-1000056-A1 | 6-PYRROLIDIN-2-YLPYRINDINE DERIVATIVES, THEIR PREPARATION AND APPLICATION IN THERAPY | SANOFI-SYNTHELABO (FR) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002517-A1 | 6-PYRROLIDIN-2-YLPYRINDINE DERIVATIVES, THEIR PREPARATION AND APPLICATION IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-01-21 | — | — | WO | disclosed |
| US-4684728-A | Solubilizing biologically active compounds with reactive hydrogen atoms | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486276-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | DTYMK, DCK, MAP3K9 | CHRNB2 4506/4885CHRNA4 4103/4885CHRNA7 4176/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | CHRNB2 3495/4885CHRNA4 3891/4885CHRNA7 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.